Actar explores innovative drug targets in multiple therapeutic areas resulting from academic research at top European institutions. Actar collaborates with the academic researchers to perform drug discovery based on these targets.
Aiming to discover proprietary compounds with validated effect in relevant disease models, Actar brings its expertise in drug research and project management together with therapeutic area competency of the academic researchers. Drug-like compounds active against these targets are identified, characterized and divested, or further developed in collaboration with larger pharmaceutical companies.
Actar AB will, through high throughput screening of chemical libraries and further drug development, identify and optimize lead compound that are active against targets generated in previous WPs. The aim is to optimize a lead compound and thereafter divest the project to the pharmaceutical industry for further clinical development, and in the end to the cancer patient.
In addition facilitating knowledge in medicinal chemistry and high-throughput screening, Actar AB also manages and finances the first steps of the development process by offering project management, funding for patent protection, legal advice, and business development. Further, Actar AB continuously evaluates projects through a Scientific Advisory Board ensuring optimal evaluation of all projects in collaboration with leading clinical experts, market analysts and pattern advisors.
List of persons involved in MetaFight
- Mathias Alterman, PhD - Medicinal chemist
- Ulrika Bäckman, PhD - In Vivo pharmacologist
- Delal Öncü, Bs - Lab technician